Quarter
Charts

KYMERA THERAPEUTICS, INC.

KYMR

CIK 0001815442 · Quarterly mode · latest period FY2026 (Q1) (ending 2026-03-31) · sourced from SEC EDGAR

At a glance · FY2026 (Q1)

Revenue
$34M
↑+55.5% +$12Mvs FY2025 (Q1)
Gross Profit
$0

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
33/100
  • Profitability
    0ROIC -22.9% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 10.47 (above 1.5 = solid)
  • Leverage
    0Insufficient data
  • Efficiency
    0Asset Turnover 0.03x (1.0+ = capital-efficient)
  • Growth
    100Revenue YoY +55.5% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Op Margin -244.9% · trend -621.9pts (4Q avg vs prior 4Q)

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Capital allocation · trailing 4 quarters

how the company spent its cash
Capex (TTM)
$1M
investment in PP&E
Stock-based comp (TTM)
$62M
non-cash dilution

Balance sheet · 2026-03-31

latest filed snapshot
Total assets
$1.67B
everything owned
Total liabilities
$129M
everything owed
Stockholders' equity
$1.54B
shareholder claim

Recent performance · 27 quarters

Revenue↑+55.5% +$12M
$34M
Net Income↓-5.6% -$4M
$-69M
Free Cash Flow↓-12.1% -$10M
$-89M
Operating Margin↑+91.9pts
-244.9%

Drill down

KYMR Sankey

See KYMERA THERAPEUTICS, INC.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

KYMR Charts

27 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

KYMR Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics